NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immunemediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:3 ...